Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease.
Adolescent
Adult
Aged
Autoantibodies
/ blood
Cohort Studies
Female
Humans
Immunosuppressive Agents
/ therapeutic use
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
/ blood
Myelin-Oligodendrocyte Glycoprotein
/ blood
Neuromyelitis Optica
/ blood
Retrospective Studies
Rituximab
/ therapeutic use
Treatment Outcome
Young Adult
MOG antibodies
Multiple sclerosis
Neuromyelitis optica
Propensity score
Treatment response
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
02 Jul 2019
02 Jul 2019
Historique:
received:
21
12
2018
accepted:
19
06
2019
entrez:
4
7
2019
pubmed:
4
7
2019
medline:
7
1
2020
Statut:
epublish
Résumé
Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease. This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment. Median age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab. In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD.
Sections du résumé
BACKGROUND
BACKGROUND
Myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) are related to several acquired demyelinating syndromes in adults, but the therapeutic approach is currently unclear. We aimed to describe the response to different therapeutic strategies in adult patients with relapsing MOG-Ab-associated disease.
METHODS
METHODS
This is a retrospective study conducted in France and Spain including 125 relapsing MOG-Ab patients aged ≥ 18 years. First, we performed a survival analysis to investigate the relapse risk between treated and non-treated patients, performing a propensity score method based on the inverse probability of treatment weighting. Second, we assessed the annualised relapse rates (ARR), Expanded Disability Status Scale (EDSS) and visual acuity pre-treatment and on/end-treatment.
RESULTS
RESULTS
Median age at onset was 34.1 years (range 18.0-67.1), the female to male ratio was 1.2:1, and 96% were Caucasian. At 5 years, 84% (95% confidence interval [CI], 77.1-89.8) patients relapsed. At the last follow-up, 66 (52.8%) received maintenance therapy. Patients initiating immunosuppressants (azathioprine, mycophenolate mophetil [MMF], rituximab) were at lower risk of new relapse in comparison to non-treated patients (HR, 0.41; 95CI%, 0.20-0.82; p = 0.011). Mean ARR (standard deviation) was reduced from 1.05(1.20) to 0.43(0.79) with azathioprine (n = 11; p = 0.041), from 1.20(1.11) to 0.23(0.60) with MMF (n = 11; p = 0.033), and from 1.08(0.98) to 0.43(0.89) with rituximab (n = 26; p = 0.012). Other immunosuppressants (methotrexate/mitoxantrone/cyclophosphamide; n = 5), or multiple sclerosis disease-modifying drugs (MS-DMD; n = 9), were not associated with significantly reduced ARR. Higher rates of freedom of EDSS progression were observed with azathioprine, MMF or rituximab.
CONCLUSION
CONCLUSIONS
In adults with relapsing MOG-Ab-associated disease, immunosuppressant therapy (azathioprine, MMF and rituximab) is associated with reduced risk of relapse and better disability outcomes. Such an effect was not found in the few patients treated with MS-DMD.
Identifiants
pubmed: 31266527
doi: 10.1186/s12974-019-1525-1
pii: 10.1186/s12974-019-1525-1
pmc: PMC6607517
doi:
Substances chimiques
Autoantibodies
0
Immunosuppressive Agents
0
Myelin-Oligodendrocyte Glycoprotein
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
134Références
Ann Neurol. 2007 Apr;61(4):300-6
pubmed: 17444502
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Eur J Neurol. 2010 Aug;17(8):1019-32
pubmed: 20528913
Arch Neurol. 2010 Aug;67(8):1016-7
pubmed: 20697055
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neurology. 2011 Apr 12;76(15):1310-5
pubmed: 21482945
Neurology. 2011 Aug 16;77(7):659-66
pubmed: 21813788
J Neuroinflammation. 2011 Dec 28;8:184
pubmed: 22204662
Mult Scler. 2013 Sep;19(10):1261-7
pubmed: 23572237
J Neurol. 2014 Jan;261(1):1-16
pubmed: 24272588
Neurology. 2014 Feb 11;82(6):474-81
pubmed: 24415568
JAMA Neurol. 2014 Mar;71(3):276-83
pubmed: 24425068
J Neurol Sci. 2014 Apr 15;339(1-2):223-5
pubmed: 24576801
PLoS One. 2014 Jun 02;9(6):e98192
pubmed: 24887452
Nat Rev Neurol. 2014 Sep;10(9):493-506
pubmed: 25112508
JAMA Neurol. 2014 Nov;71(11):1372-8
pubmed: 25199960
Mult Scler. 2015 Jun;21(7):866-874
pubmed: 25344373
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(2):e81
pubmed: 25798445
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
J Neurol. 2015 Oct;262(10):2329-35
pubmed: 26194198
Mult Scler. 2016 Jun;22(7):955-9
pubmed: 26362900
Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e163
pubmed: 26516628
Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225
pubmed: 27144216
J Neurol. 2016 Jul;263(7):1349-60
pubmed: 27147513
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257
pubmed: 27458601
Stat Med. 2016 Dec 30;35(30):5642-5655
pubmed: 27549016
JAMA Neurol. 2016 Nov 1;73(11):1342-1348
pubmed: 27668357
J Neuroinflammation. 2016 Sep 26;13(1):279
pubmed: 27788675
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
J Neuroinflammation. 2016 Nov 1;13(1):281
pubmed: 27802825
Mult Scler. 2017 Sep;23(10):1377-1384
pubmed: 27885065
Curr Opin Neurol. 2017 Jun;30(3):208-215
pubmed: 28306572
Brain. 2017 Mar 1;140(3):617-627
pubmed: 28364548
Neurology. 2017 Aug 29;89(9):900-908
pubmed: 28768844
J Neurol. 2017 Sep;264(9):1945-1955
pubmed: 28770374
JAMA Neurol. 2018 Jan 1;75(1):65-71
pubmed: 29131884
Brain. 2017 Dec 1;140(12):3128-3138
pubmed: 29136091
J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137
pubmed: 29142145
JAMA Neurol. 2018 Apr 1;75(4):478-487
pubmed: 29305608
Neurology. 2018 May 22;90(21):e1858-e1869
pubmed: 29695592
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224